Lung Cancer | Specialty

Pivotal Data Demonstrate Importance of Lung Cancer Screening

March 3rd 2020

Michael K. Gould, MD, MS, discusses pivotal lung cancer screening trials and their impact on clinical practice.

Dr. Natale on the Utility of PD-L1 and TMB in Lung Cancer

March 3rd 2020

Ronald B. Natale, MD, medical director, Clinical Lung Cancer Program and assistant clinical professor of medicine, Cedars-Sinai, discusses the utility of PD-L1 expression and tumor mutational burden (TMB) in lung cancer.

Brigatinib Nears EU Approval for Frontline ALK+ NSCLC

March 2nd 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer

Dr. Ramchandran on Considerations for Palliative Care in Thoracic Cancers

February 29th 2020

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Dr. Piotrowska on Eligibility Criteria for Osimertinib in Lung Cancer Treatment

February 29th 2020

Zofia Piotrowska, MD, MHS, discusses the patient populations eligible to receive osimertinib as treatment for lung cancer.

Small-Cell Lung Cancer: Future Directions in Care

February 28th 2020

Emerging Treatment Options for SCLC

February 28th 2020

Lurbinectedins Role in Managing SCLC

February 28th 2020

Treatment of Relapsed/Refractory SCLC

February 28th 2020

Chemoimmunotherapy for ES SCLC: CASPIAN Trial

February 28th 2020

Chemoimmunotherapy for ES SCLC: IMpower133 Trial

February 28th 2020

Addressing the Aggressive Nature of SCLC

February 28th 2020

Optimal Management of Limited-Stage SCLC

February 28th 2020

SCLC Overview: Presentation, Staging, and Complications

February 28th 2020

Dr. Chae on Using Crizotinib to Treat MET+ NSCLC

February 28th 2020

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLC

February 28th 2020

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Immunotherapy Makes Waves in Small Cell Lung Cancer

February 28th 2020

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

FDA Panel Narrowly Supports Ramucirumab/Erlotinib Combo in Frontline EGFR+ NSCLC

February 27th 2020

The FDA's Oncologic Drugs Advisory Committee voted 6 to 5 in favor of intravenous ramucirumab injection for use in combination with erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.

Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer

February 27th 2020

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

FDA Grants Brigatinib Priority Review for Frontline ALK+ NSCLC

February 24th 2020

The FDA has granted a priority review designation to a supplemental New Drug Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.